Macrophage-evading and tumor-specific apoptosis inducing nanoparticles for targeted cancer therapy

Liu, Zimo; Zhou, Xuefei; Li, Qi; Shen, Youqing; Zhou, Tianhua; Liu, Xiangrui

doi:10.1016/j.apsb.2022.05.010

Cited by 19 publications

(19 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that conventional PLGA NPs, after systemic administration, are removed from the bloodstream within 10 min, significantly impairing their therapeutic efficacy and targeting capability [ 37 ]. Additionally, the stability of membrane-coated nanocarriers is considerably enhanced due to their increased capacity to evade systemic clearance and macrophage uptake [ 38 ]. In addition, biomimetic nanocarriers can reduce drug leakage in physiological conditions [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment

et al. 2022

View full text Add to dashboard Cite

Currently, breast-cancer treatment has a number of adverse side effects and is associated with poor rates of progression-free survival. Therefore, a radiolabeled anti-EpCAM targeted biomimetic coated nanocarrier (EINP) was developed in this study to overcome some of the treatment challenges. The double emulsion method synthesized the poly(lactic-co-glycolic acid) (PLGA) nanoparticle with Na131I entrapped in the core. The PLGA nanoparticle was coated in human red blood cell membranes and labeled with epithelial cell adhesion molecule (EpCAM) antibody to enable it to target EpCAM overexpression by breast-cancer cells. Characterization determined the EINP size as 295 nm, zeta potential as −35.9 mV, and polydispersity as 0.297. EINP radiochemical purity was >95%. Results determined the EINP efficacy against EpCAM positive MCF-7 breast cancer at 24, 48, and 72 h were 69.11%, 77.84%, and 74.6%, respectively, demonstrating that the EINPs achieved greater cytotoxic efficacy supported by NIS-mediated Na131I uptake than the non-targeted 131INPs and Na131I. In comparison, fibroblast (EpCAM negative) treated with EINPs had significantly lower cytotoxicity than Na131I and 131INPs (p < 0.05). Flow cytometry fluorescence imaging visually signified delivery by EINPs specifically to breast-cancer cells as a result of anti-EpCAM targeting. Additionally, the EINP had a favorable safety profile, as determined by hemolysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In mouse tumor models of in situ hepatocellular carcinoma and colorectal cancer peritoneal metastasis, TM–CQ/NP accumulated in tumor tissue and had excellent antitumor activity (Figure 15C,D). [ 105 ] In addition to using cell membranes as vectors for genetically engineered TRAIL expression, bacterial membranes can also be used as a delivery vector. Ning and co‐workers obtained derived outer membrane vesicles by expressing TRAIL on the surface of Escherichia coli using genetic engineering techniques.…”

Section: Application Of Gcmns In Cancer Immunotherapymentioning

confidence: 99%

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy

et al. 2023

View full text Add to dashboard Cite

The advent of immunotherapy has marked a new era in cancer treatment, offering significant clinical benefits. Cell membrane as drug delivery materials has played a crucial role in enhancing cancer therapy because of their inherent biocompatibility and negligible immunogenicity. Different cell membranes are prepared into cell membrane nanovesicles (CMNs), but CMNs have limitations such as inefficient targeting ability, low efficacy, and unpredictable side effects. Genetic engineering has deepened the critical role of CMNs in cancer immunotherapy, enabling genetically engineered‐CMN (GCMN)‐based therapeutics. To date, CMNs that are surface modified by various functional proteins have been developed through genetic engineering. Herein, a brief overview of surface engineering strategies for CMNs and the features of various membrane sources is discussed, followed by a description of GCMN preparation methods. The application of GCMNs in cancer immunotherapy directed at different immune targets is addressed as are the challenges and prospects of GCMNs in clinical translation.

show abstract

“…As is known to all, an extension of anticancer drugs in blood circulation is essential to the curative effect, however, the mononuclear phagocyte system can quickly isolate and remove drug-loading NPs. Liu et al produced biomimetic NPs coated with fibroblast membranes expressing TNF-related apoptosis-inducing ligand (TRAIL) while loaded with chloroquine (CQ), referred to as TM-CQ/NPs, which are not only reduced macrophage phagocytosis and escaped from the endothelial reticulation system, but also targeted tumor tissue and increased uptake of NPs by tumor cells 188 (Fig. 22).…”

Section: Nps For Chemotherapeutic Drug Deliverymentioning

confidence: 99%

Design and fabrication of intracellular therapeutic cargo delivery systems based on nanomaterials: current status and future perspectives

Xing

Zhou

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Macrophage-evading and tumor-specific apoptosis inducing nanoparticles for targeted cancer therapy

Cited by 19 publications

References 64 publications

Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment

Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy

Design and fabrication of intracellular therapeutic cargo delivery systems based on nanomaterials: current status and future perspectives

Contact Info

Product

Resources

About